Gilead Sciences Stock Analysis (NASDAQ:GILD)

Add to My Stocks
$64.31 $0.38 (0.59%) GILD stock closing price May 24, 2017 (Closing)
Watch Robo Advisor Video of GILD Stock Analysis
Gilead Sciences
Updated on : May 24, 2017
previous close
GILD 64.3 (0%)
S&P 500 2404.4 (0%)
Closing Price On: May 24, 2017
stock rating
RATING: ★★★★★★★★★★ (0/5)
Industry :
Medical-Biomed-Genetics
Sector :
Medical
5 Quarter Revenue
Revenue Growth
2017-Q1
$billion
%
YOY GROWTH
Compared to the industry
Operating Profit
Operating Margin:
57.6%
Sector Average:
1.1%
5 Quarter Net Profit
Net Margins
2017-Q1
%
LTM Margin
Compared to the industry
Debt/Equity Ratio
Debt:
26.32B
Debt/Equity Ratio:
 1.26
Compared to the industry
Cash Flow
Operating cash flow:
$2.93B
Net Income:
$2.7B
Dividend Yield
GILD dividend yield:
3%
PROS      CONS
Operating Margins
Net Margins
ROIC
ROE
FCF Margin
PE Valuation
Recent Growth
High Debt Burden
Rating: ★★★★★★★★★★ (0/5)
Relative Valuation
GILD PS :
2.9
Industry PS :
4.5
Sector:   Medical.   *PE adjusted for one time items.
Other Metrics
Return on Invested Capital:
45.5%
Return on Equity:
72%
Free Cash Flow Margin:
43.2%
Double Tap To Exit Full Screen
0:00
/

Gilead Sciences Analysis Video

6924 9 2

View Gilead Sciences stock analysis video. This is our GILD analyst opinion covering the buy and sell arguments for GILD stock.

Gilead Sciences, Inc. Stock Rating (4.1/5)

Our Gilead Sciences stock opinion is based on fundamentals of the company. This Gilead Sciences stock analysis is based on latest Q1 earnings for 2017. The stock price analysis takes into account a company's valuation metrics.

Should you buy GILD stock?

  • Gilead Sciences had a healthy average operating margin of 57.6% over the last 4 quarters.
  • LTM Net margins were good at 43.4% for Gilead Sciences.
  • The price to earnings multiple of 6.1 is attractive when compared with the industry average PE ratio of 22.4.
  • When compared with the Medical-Biomed-Genetics industry average PS ratio of 4.5, the price-to-sales ratio of 2.9 for GILD stock is attractive.
  • Gilead Sciences has an attractive ROIC (Return on Invested Capital) of 45.5%
  • Gilead Sciences has a good Return On Equity (ROE) of 72%.
  • The company has a good Free Cash Flow (FCF) margin of 43.2%.

Should you sell GILD stock?

  • Gilead Sciences sales shrank by -16.5% year-over-year in 2017 Q1.
  • Gilead Sciences has a debt/equity ratio of  1.26, which is worse than the average in the Medical sector.

Comments on this video and Gilead Sciences stock